Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 33,170 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Healthy
Interventions: Vitamin D3 1000 IU, Placebo Tablet; Dietary Supplement
Lead sponsor: University of Pittsburgh; Other
Eligibility: 8 Years to 14 Years
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Tobacco Use Disorder
Interventions: varenicline, Adaptation of Motivational Interviewing; Drug · Behavioral
Lead sponsor: VA Boston Healthcare System; Federal
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Brockton, Massachusetts

Conditions: Oxytocin, Placebo
Interventions: intranasal oxytocin, Placebo, Social support, No Social Support; Drug · Behavioral
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: 22 Years to 65 Years
Enrollment: 270 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Herpes Simplex Virus
Interventions: Novel Antiviral Drug, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 1 Day to 98 Days
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 18
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 15 more

Conditions: Type 1 Diabetes
Interventions: Acipimox, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 25 Years to 59 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Heart Failure
Interventions: ivabradine, Usual Care; Drug · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 20
States / cities: Aurora, Colorado • Fort Lauderdale, Florida • Athens, Georgia + 17 more

Conditions: Excessive Sleepiness
Interventions: Armodafinil, Matching Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 385 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 63
States / cities: Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 56 more

Conditions: Gastroparesis
Interventions: GSK962040 50 mg, Metoclopramide 10 mg, Placebo NG, Placebo IV; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 4
States / cities: Aurora, Colorado • Augusta, Georgia • Louisville, Kentucky + 1 more

Conditions: Obesity
Interventions: Whey Protein supplement, Soy Protein Supplement, Carbohydrate supplement; Dietary Supplement
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years to 30 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Lawrence, Kansas

Conditions: Type 2 Diabetes Mellitus
Interventions: KD026, Placebo, Metformin; Drug
Lead sponsor: Response Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Birmingham, Alabama • Los Angeles, California • West Hills, California + 6 more

Conditions: Hypertension
Interventions: grape seed extract, grape seed extract placebo; Dietary Supplement
Lead sponsor: Clinical Nutrition Research Center, Illinois Institute of Technology; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Opioid-use Disorder, Opioid-Related Disorders
Interventions: Open-Label Placebo (OLP); Behavioral
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alzheimer's Disease
Interventions: Placebo, ABT-126, donepezil; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 55 Years to 90 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Fresno, California • West Palm Beach, Florida • Indianapolis, Indiana

Conditions: Genital Psoriasis, Psoriasis
Interventions: Ixekizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 13
States / cities: Santa Ana, California • Santa Monica, California • Tampa, Florida + 9 more

Conditions: Delta-9-Tetrahydroncannabinol, Bipolar Disorder, Healthy Controls
Interventions: 4 mg Delta-9-THC, Placebo, 2 mg Delta-9-THC; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Alcohol Use Disorder
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: Oklahoma State University Center for Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Peanut Allergy
Interventions: Etokimab, Placebo; Drug
Lead sponsor: AnaptysBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Palo Alto, California • Seattle, Washington

Conditions: Schizophrenia
Interventions: Bifeprunox, Quetiapine; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 69
States / cities: Anaheim, California • Cerritos, California • Costa Mesa, California + 52 more

Conditions: Opioid Use Disorder
Interventions: Buprenorphine; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 5
States / cities: Oakland, California • San Leandro, California • Portland, Maine + 2 more

Conditions: RSV Illness in ≤12 Months of Participants
Interventions: Motavizumab, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 0 Months to 12 Months
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 26
States / cities: Tucson, Arizona • Long Beach, California • Orange, California + 23 more

Conditions: Fragile x Syndrome
Interventions: Ganaxolone, Placebo; Drug
Lead sponsor: Marinus Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Sacramento, California

Conditions: People With Identified Painful Trigger Points (Tp) Within the Soleus and Gastrocnemius Muscles Complex, Healthy Subjects or Volunteers
Interventions: Dry needling with electrical stimulation, Dry needling, Electrical stimulation, Sham; Procedure
Lead sponsor: University of Rhode Island; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Kingston, Rhode Island

Conditions: Spinal Cord Injury (SCI)
Interventions: Elezanumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 22
States / cities: Sacramento, California • Atlanta, Georgia • Chicago, Illinois + 15 more

Conditions: Erectile Dysfunction
Interventions: Placebo, Tadalafil; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 372 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3

Treating Schizophrenic Smokers: Effects on Craving, Cues and Withdrawal

The Biology of Resilience

A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)

Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes

Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)

Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work Disorder

Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study

Whey Protein, Resistance Training, and Changes in Body Composition

Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus

The Effect of Grape Seed Extract on Blood Pressure in People With Pre-Hypertension

Harnessing Placebo Effects in Methadone Treatment

Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis

Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder

Semaglutide Therapy for Alcohol Reduction - Tulsa

Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy

Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients

Standard Versus High Dose ED-Initiated Buprenorphine Induction

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

Ganaxolone Treatment in Children With Fragile X Syndrome

Trigger Point Dry Needling With and Without Electrical Stimulation in Healthy Subjects

Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

A Study in Erectile Dysfunction